Clinical trials: Adjuvant
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
Vaginal Atrophy
A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in…
- Trial name
- BLISSAFE (NCT02413008)
- Testing
- estriol
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 61 people
- Sponsor
- ITF Research Pharma, S.L.U.
Swine-Origin Influenza A H1N1 Virus
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects
This study is to identify the preferred vaccine dosage (of antigen and adjuvant) and schedule (one or two administrations) of the cell-derived H1N1sw monovalent vaccine in healthy children/adolescents based on European Medicines…
- Trial name
- NCT01000207
- Testing
- Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine
- Where
- Japan
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Upper Respiratory Tract Infections, Pharyngitis
Efficacy and Safety of L. Plantarum and P. Acidilactici in Children With Upper Respiratory Tract Infections
Randomized, placebo-controlled trial to evaluate the coadjuvant effect of a combination of L. plantarum and P. acidilactici probiotic strains, taken twice daily, in children 6 months to 5 years-old with upper respiratory tract…
- Conditions
- Upper Respiratory Tract Infections, Pharyngitis, Tonsillitis
- Trial name
- NCT05279534
- Testing
- Probiotic
- Where
- Mexico
- Volunteers
- 80 people
- Sponsor
- AB Biotics, SA
Melanoma
An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma
The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a…
- Trial name
- CheckMate 915 (NCT03068455)
- Testing
- nivolumab, ipilimumab
- Where
- 124 sites in United States, Australia and 17 more
- Volunteers
- 1,844 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 Years
The purpose of this study was to assess the difference in disease-free survival between post-menopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued…
- Trial name
- NCT00286117
- Testing
- Anastrozole, Tamoxifen
- Where
- 25 sites in Italy
- Volunteers
- 448 people
- Sponsor
- AstraZeneca
Breast Cancer
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
The purpose of this survey is to describe long-term tolerance as seen under current conditions of use for anastrozole.
- Trial name
- ARIES (NCT00542594)
- Volunteers
- 1,840 people
- Sponsor
- AstraZeneca
Sarcoma
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Sarcoma patients are at high risk for their cancer to recur even when the sarcoma has been removed surgically or treated with radiation or chemotherapy.
- Trial name
- NCT01141491
- Testing
- Trivalent ganglioside vaccine, OPT-821
- Where
- 13 sites in United States
- Volunteers
- 136 people
- Sponsor
- MabVax Therapeutics, Inc.
Vulvovaginal Candidiasis (VVC)
Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis
Open-label, randomized clinical trial with a control group and a 4-week intervention period. The study will evaluate the efficacy of the probiotic supplement Bioithas WOMAN® as an adjunctive treatment in women with clinically…
- Trial name
- NCT07603895
- Testing
- Bioithas WOMAN®
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Bioithas SL
Melanoma
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
- Trial name
- RELATIVITY-098 (NCT05002569)
- Testing
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 1,093 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis, Atopic Dermatitis Eczema
The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (14 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
- Trial name
- NCT05719649
- Testing
- Lactic acid bacteria NTU 101
- Volunteers
- 72 people
- Sponsor
- SunWay Biotech Co., LTD.
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children.
- Trial name
- NCT00972816
- Testing
- MF59-eH1N1
- Where
- 35 sites in United States, Mexico
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Melanoma
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.
- Trial name
- CheckMate 238 (NCT02388906)
- Testing
- Ipilimumab, Nivolumab
- Where
- 136 sites in United States, Argentina and 23 more
- Volunteers
- 906 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.
- Trial name
- NCT03553836
- Testing
- Pembrolizumab
- Where
- 159 sites in United States, Australia and 14 more
- Volunteers
- 976 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).
- Trial name
- NCT05665595
- Testing
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,594 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
- Trial name
- NCT02049905
- Testing
- Aldoxorubicin, Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 433 people
- Sponsor
- ImmunityBio, Inc.
Melanoma
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
The purpose of this study is to evaluate the role of neoadjuvant immunotherapy and to demonstrate high pathologic complete response (pCR) and near pCR rates in melanoma participants with clinically detectable nodal disease and a…
- Trial name
- CheckMate 7UA (NCT04495010)
- Testing
- Nivolumab, Ipilimumab
- Where
- 118 sites in United States, Australia and 14 more
- Sponsor
- Bristol-Myers Squibb
Colonic Neoplasms, Colorectal Neoplasms
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus [ChAd] and…
- Trial name
- NCT05456165
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 3 sites in United States
- Sponsor
- Gritstone bio, Inc.
Breast Cancer
Liver Safety Under Upfront Arimidex vs Tamoxifen
The primary objective is to compare ARIMIDEX (anastrozole) 1 mg once daily with Tamoxifen 20 mg once daily as adjuvant treatment in terms of: incidence of fatty liver diseases.
- Trial name
- HEART (NCT00537771)
- Testing
- Anastrozole, Tamoxifen
- Where
- 16 sites in China
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Melanoma, Adjuvant
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
The purpose of this Treatment Plan is to allow access to trametinib and dabrafenib for eligible high-risk BRAF mutation-positive patients in the adjuvant treatment of melanoma after surgical resection.
- Trial name
- NCT04544202
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals